Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by Stylesson Mar 10, 2015 6:02pm
102 Views
Post# 23507285

RE:RE:RE:Patent settlement April 2015, more drugs buys more earnings

RE:RE:RE:Patent settlement April 2015, more drugs buys more earnings i actually flagged the one drug risk prior to the pattent challenge and the stock cratered after. I dont see how i was wrong there. It's still a big concern. this company is still a one drug wonder. People are just taking comfort in the fact that it's a cashed up company and they will likely do more deals. I'm a bit surprised they haven't bought something material. Probably their biggest mistake to date was not buying a mature cash flowing drug by now. 

Why would i want CPH shares. Charts broken, mature drug now with limited incremental market share opportunitiy. Rather on CRH, GUD, CXR. Whli you lost +50% from the peak, i made money playing those stocks that are up more than CPH.

Good luck. the stock is currently not a buy imo.
Bullboard Posts